Estimaciones de analistas de Wall Street para Trevi Therapeutics, Inc. (TRVI): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-11-12 | $-0.13 | ||
| 2026-08-06 | $-0.11 | $-0.11 | -0.5% |
| 2026-05-05 | $-0.09 | $-0.07 | -28.6% |
| 2026-03-17 | $-0.06 | $-0.10 | +40.0% |
| 2025-11-13 | $-0.08 | $-0.10 | +20.0% |
| 2025-08-07 | $-0.09 | $-0.10 | +10.0% |
| 2025-05-08 | $-0.09 | $-0.13 | +30.8% |
| 2025-03-18 | $-0.11 | $-0.12 | +8.3% |
Ratios de valoración
| Precio / Valor contable | 7.33 |
| EV / EBITDA | -40.70 |
| Rentabilidad por dividendo | 0.00% |
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Coste de Ventas | $4000 | 0 | $23000 | $39000 | $47000 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Bruto | -$4000 | 0 | -$23000 | -$39000 | -$47000 | 0 | 0 | 0 | 0 | 0 |
| I+D | $6.9M | $6.1M | $14.1M | $19.3M | $22.3M | $23.0M | $19.8M | $23.7M | $39.4M | $33.5M |
| Generales y Administrativos | $1.7M | $2.1M | $4.3M | $7.3M | $10.2M | $9.5M | $10.1M | $10.2M | $12.1M | $15.8M |
| Gastos Operativos | $8.6M | $8.2M | $18.4M | $26.6M | $32.5M | $32.5M | $29.9M | $33.9M | $51.5M | $49.3M |
| Beneficio Operativo | -$8.6M | -$8.2M | -$18.4M | -$26.6M | -$32.5M | -$32.5M | -$29.9M | -$33.9M | -$51.5M | -$49.3M |
| EBITDA | -$8.6M | -$8.2M | -$18.4M | -$26.6M | -$32.3M | -$32.7M | -$28.0M | -$28.6M | -$47.8M | -$42.7M |
| Gastos por Intereses | 0 | $3.3M | $174000 | 0 | $456000 | $1.2M | $780000 | $391000 | $4000 | 0 |
| Beneficio Antes de Impuestos | -$11.1M | -$12.9M | -$20.7M | -$26.1M | -$32.8M | -$34.0M | -$29.2M | -$29.1M | -$47.9M | -$42.8M |
| Impuestos | -$8000 | -$26000 | -$124000 | -$18000 | -$18000 | -$21000 | -$36000 | -$32000 | -$30000 | -$64000 |
| Beneficio Neto | -$11.1M | -$12.9M | -$20.5M | -$26.1M | -$32.8M | -$33.9M | -$29.2M | -$29.1M | -$47.9M | -$42.8M |
| BPA | $-0.69 | $-1.43 | $-2.29 | $-1.46 | $-1.81 | $-1.49 | $-0.45 | $-0.29 | $-0.47 | $-0.29 |
| BPA Diluido | $-0.69 | $-1.43 | $-2.29 | $-1.46 | $-1.81 | $-1.49 | $-0.45 | $-0.29 | $-0.47 | $-0.29 |
| Acciones en Circulación (Diluidas) | $16.1M | $9.0M | $9.0M | $17.8M | $18.1M | $22.8M | $64.5M | $99.0M | $101.0M | $145.1M |
Precio
| Precio | $15.89 |
| Capitalización | $2.3B |
| Bolsa | NASDAQ |
| País | US |
Empresas relacionadas: ARDX · NVAX · ORIC · PGEN · TERN · TRML · UPB
Explorar sector: Healthcare · Biotechnology
Más secciones de TRVI: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones